Ikena Oncology, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
ImageneBio, Inc. filed its Q2 2026 Form 10-Q, detailing continued investment in its lead drug candidate, olevaprubart, while reporting net losses and a material weakness in internal controls.
ImageneBio, Inc. reports significant cash increase post-merger and PIPE financing, while advancing its lead asset IMG-007 for atopic dermatitis despite ongoing losses and an identified material weakness in internal controls.
10-Q: Ikena Oncology Reports Q2 2025 Losses Amidst Strategic Merger with Inmagene Biopharmaceuticals
Ikena Oncology, Inc. reported continued net losses in Q2 2025 as it winds down its internal clinical programs and progresses towards a strategic merger with Inmagene Biopharmaceuticals, approved by stockholders.
Ikena Oncology's Q1 2025 results reflect reduced operating expenses amid a strategic merger with Inmagene Biopharmaceuticals, with the merger and related financing expected to close in mid-2025.
Ikena Oncology's Q3 2024 report highlights a strategic shift towards clinical-stage programs, particularly IK-595, alongside a significant workforce reduction and ongoing exploration of strategic options.
Ikena Oncology announced its second quarter 2024 results, highlighting a strategic shift towards its IK-595 program and a reduction in workforce, while also exploring strategic options for the company.
Ikena Oncology's first quarter 2024 results show a net loss of $16.1 million, with a strategic shift towards clinical-stage programs and a workforce reduction.